Moderna, Inc. vs Teucrium Soybean Fund — how do they compare? Moderna, Inc. trades at $206.52 (market cap $78.65B), while Teucrium Soybean Fund trades at $27.58 (market cap $43.52M). The key difference: Moderna, Inc. is far larger — about 1807.2× Teucrium Soybean Fund's market cap, and Moderna, Inc. is trading nearer its 52-week high, Teucrium Soybean Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Teucrium Soybean Fund for 23 Days on average.
| MRNA | SOYB | |
|---|---|---|
Market Cap | $78.65B | $43.52M |
Volume | 37,373,437 | 32,585 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $203.46 | $28.14 |
52-Week Low | $22.36 | $21.55 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $74.80B | — |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →